Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocarnitine for Nonalcoholic Fatty Liver Disease
ChiCTR-IPR-16008718Phase 4Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Levocarnitine with Placebo/No treatment control (2 arms). Primary endpoint: ALT level. Started Jun 2016; status: recruiting.
02
Drugs
levocarnitine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR-IPR-16008718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008718.